COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00102934
Recruitment Status : Unknown
Verified September 2008 by National Institute of Allergy and Infectious Diseases (NIAID).
Recruitment status was:  Active, not recruiting
First Posted : February 7, 2005
Last Update Posted : September 17, 2008
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them. The purpose of this study is to test the effectiveness of a short, intensified course of anti-HIV drugs for controlling HIV infection in adults who have virus resistant to multiple drugs.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Enfuvirtide-intensified HAART Not Applicable

Detailed Description:

While an HIV infected patient is taking highly active antiretroviral therapy (HAART), drug-resistant HIV may emerge; however, it has been observed that HIV viral loads while on HAART are usually lower than baseline levels. Expansion of the T cell population during early HAART may explain this phenomenon. It is hoped that a short but aggressive HAART regimen to treatment-experienced patients who have drug-resistant virus will produce immune cells that will better control drug-resistant virus. This study will determine if a 6-month HAART regimen intensified by enfuvirtide (T-20) is effective in eliciting a stronger immune response against drug-resistant virus.

This study will last 48 weeks. All participants will receive T-20 as part of a HAART intensification regimen; HAART other than T-20 will not be provided by the study. There will be 17 study visits. Prior to beginning treatment intensification, participants will have weekly study visits for three weeks. Once treatment intensification has started, participants will be followed weekly for four weeks, then weekly for four weeks after treatment intensification, then monthly thereafter. Blood collection will occur at each visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment Intensification in HIV-1 Patients With Multi-Drug Resistant Virus
Study Start Date : March 2003
Actual Primary Completion Date : December 2005
Estimated Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
Drug Information available for: Enfuvirtide

Arm Intervention/treatment
Experimental: 1
Participants will receive enfuvirtide for 6 months
Drug: Enfuvirtide-intensified HAART
90 mg tablet taken orally twice daily
Other Names:
  • T-20
  • Fuzeon

Primary Outcome Measures :
  1. HIV viral load [ Time Frame: Throughout study ]

Secondary Outcome Measures :
  1. Frequency of HIV-specific T cells [ Time Frame: Thoughout study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV viral load of more than 1000 copies/ml
  • On stable antiretroviral therapy
  • Have multidrug resistance

Exclusion Criteria:

  • Require immunomodulatory drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00102934

Layout table for location information
United States, California
San Francisco General Hospital
San Francisco, California, United States, 94110
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Layout table for investigator information
Principal Investigator: Steven G. Deeks, MD Department of Medicine, University of California - San Francisco

Layout table for additonal information
Responsible Party: Steven G. Geeks, MD, Department of Medicine, University of California - San Francisco Identifier: NCT00102934    
Other Study ID Numbers: 5R21AI055273-02 ( U.S. NIH Grant/Contract )
Protocol 834
5R21AI055273-02 ( U.S. NIH Grant/Contract )
First Posted: February 7, 2005    Key Record Dates
Last Update Posted: September 17, 2008
Last Verified: September 2008
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Drug Resistance
Viral Fitness
HIV Specific Immunity
T Cell Activation
Drug Resistant Viremia
Treatment Experienced
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Fusion Inhibitors
Viral Fusion Protein Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents